Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

Leuk Res. 2009 Apr;33(4):547-50. doi: 10.1016/j.leukres.2008.06.005. Epub 2008 Jul 21.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Thalidomide / administration & dosage*
  • Thalidomide / adverse effects*

Substances

  • Angiogenesis Inhibitors
  • Thalidomide